1. The emerging role of TRIB3 as a gene affecting human insulin resistance and related clinical outcomes

   • Sabrina Prudente
   • Eleonora Morini
   • Vincenzo Trischitta

   Review Article 13 January 2009 Pages: 79 - 84

   

2. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities

   • Eugenia Resmini
   • Francesco Minuto
   • Diego Ferone

   Review Article 26 March 2009 Pages: 85 - 95

   

3. Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease

   • Melania Manco
   • Ugo Giordano
   • Valerio Nobili

   Original Article 07 October 2008 Pages: 97 - 104

   

4. Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus

   • Boglárka Laczy
   • Judit Cseh
   • István Wittmann

   Original Article 07 October 2008 Pages: 105 - 111

   

5. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

   • A. Nar
   • O. Gedik

   Original Article 07 October 2008 Pages: 113 - 118

6. Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats

   • Liping Zhang
   • Yaping Liu
   • Haiqin Rong

   Original Article 09 October 2008 Pages: 119 - 126

   

7. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients

   • Chen-Chung Fu
   • Du-An Wu
   • Chin-Hsiao Tseng

   Original Article 14 October 2008 Pages: 127 - 134

   

8. Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes?

   • Sandra Fernanda Nunes
   • Isabel Vitoria Figueiredo
   • Maria Margarida Caramona

   Original Article 14 October 2008 Pages: 135 - 140

9. Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels

   • Masafumi Koga
   • Hiroshi Saito
   • Soji Kasayama

   Original Article 07 October 2008 Pages: 141 - 144

   

10. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

    • Kevin M. Pantalone
    • Michael W. Kattan
    • Robert S. Zimmerman

    Original Article 05 February 2009 Pages: 145 - 154

    

11. Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

    • David S. H. Bell

    Letter to the Editor 20 March 2009 Pages: 155 - 155

12. Letter to the Editor re: the Letter to the Editor by Dr. David Samuel Henry Bell, MD regarding “The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis”

    • Robert S. Zimmerman
    • Kevin Matthew Pantalone

    Letter to the Editor 22 March 2009 Pages: 157 - 157

13. Cardiometabolic risk and educational level in adult patients with type 1 diabetes

    • J. Nádas
    • Z. Putz
    • G. Jermendy

    Short Communication 09 October 2008 Pages: 159 - 162